SecBot SecBot
SECBOTREPLAY Home › Report › QURE

QURE · uniQure announced FDA acceptance and Priority Review of its BLA for…

uniQure Inc. · PRESS-RELEASE filed Nov 2, 2026 at 07:05 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Nov 2, 2026 at 07:05 ET

uniQure announced FDA acceptance and Priority Review of its BLA for ifezuntirgene inilparvovec (AMT-130), a gene therapy for Huntington's disease, with a PDUFA target action date of May 1, 2027. The FDA plans an Advisory Committee meeting and the confirmatory Phase III trial is expected to begin screening by end of 2026. If approved, this would be the first disease-modifying treatment for Huntington's disease, a large unmet need with ~75,000 patients in the US, EU, and UK.

  • FDA accepted BLA for ifezuntirgene inilparvovec (AMT-130) for Huntington's disease under Accelerated Approval pathway
  • Granted Priority Review with PDUFA target action date of May 1, 2027
  • FDA tentatively planning an Advisory Committee meeting
  • BLA supported by 36-month Phase I/II data vs. propensity score-matched external control from Enroll-HD database

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access